Life Science

 

Analytics; Life Science
May 09, 2011 Posted by
Join our panel of experts on biopharma valuations and venture capital investment in this Web seminar as they discuss the results of SVB Analytics’ latest research findings, including operating performance, venture funding and valuations, and exit activity ...
Read More
0 Comments | Join the Discussion

Analytics; Life Science; Venture Capital
February 04, 2011 Posted by
A new analysis questions the assumption that bets in medtech companies pay off more quickly and surely than biopharma investments. However, when medical device companies win, they win big ...
Read More
0 Comments | Join the Discussion

Life Science; Startups; Venture Capital
November 08, 2010 Posted by
Venture capitalists and startup company executives who attended the latest Silicon Valley Bank SVB Showcase event were generally upbeat about prospects for  technology, life science and cleantech innovation and investment. The quarterly invitation-only pitch event brought together dozens of people from early and growth stage companies seeking to raise their next round of funding, and from venture capitalist firms.
Read More
0 Comments | Join the Discussion

Analytics; Life Science; Venture Capital
October 08, 2010 Posted by
SVB Analytics' Web seminar focuses on trends in the Life Science sector, including venture capital financing, M&A, and IPO activity.  In this free replay of the seminar, you will hear a variety of viewpoints from our expert panel of venture capitalists who have investment experience in the Life Science sector, as well as valuation and research professionals from SVB.
Read More
0 Comments | Join the Discussion

Life Science; Venture Capital
September 03, 2010 Posted by

Have you wondered how many really good life science M&A exits happen every year? Are the big guys even buying? Do these exits actually provide returns that materially affect the venture funds that are investing?

Read More
2 Comments | Join the Discussion

Life Science; Venture Capital
February 04, 2010 Posted by

Silicon Valley Bank’s Michael Hanewich, head of life sciences on the East Coast, leads an hour long conversation between entrepreneur John Mendlein, chairman of Fate Therapeutics and former CEO of Adnexus (acquired by Bristol Myers Squibb in 2007 for more

Read More
0 Comments | Join the Discussion
 
Equal Housing Lender © 2013 SVB Financial Group · Member Federal Reserve System · Member Nasdaq: SIVB
Privacy Policy · Terms of Use · About SVB · Careers · Media · Investor Relations · Feedback
 
Please wait...